BioCentury | Feb 26, 2019
Company News

CytomX R&D day reveals Probody toxicity, chopped BMS deal

...in 76 evaluable patients with advanced unresectable solid tumors in the Phase I/II PROCLAIM-CX-2009 trial, CX-2009...
...Adverse events included ocular toxicity, liver function test abnormalities, gastrointestinal disorders and nervous system disorders. CX-2009...
...Programmed cell death 1; PD-L1 (B7-H1; CD274) - Programmed cell death 1 ligand 1 Chris Lieu CD166 PDC (CX-2009) CX-072 CX-188 Bristol-Myers...
BioCentury | Feb 16, 2019
Product Development

ADCs’ inflection point

Industry is writing a new rule book for antibody-drug conjugates that could take the modality beyond the one-size-fits-all approach that has limited its success. By 2Q20, late-stage data from at least four ADCs testing new...
BioCentury | Mar 9, 2018
Company News

Pfizer ends PDC deal with CytomX

...half data from the Phase I/II PROCLAIM-CX-2009 trial of CD166 PDC (CX-2009) to treat CD-166-positive cancer. CX-2009...
...Inc. (NASDAQ:CTMX), South San Francisco, Calif. Pfizer Inc. (NYSE:PFE), New York, N.Y. Business: Cancer Jennie Walters CD166 PDC (CX-2009) CX-2029 AbbVie...
BioCentury | Jul 3, 2017
Clinical News

CytomX begins Phase I/II of CX-2009 in solid tumors

...CytomX Therapeutics Inc. (NASDAQ:CTMX) began the open-label, U.S. Phase I/II PROCLAIM-CX-2009 trial to evaluate CD166 PDC (CX-2009...
...will evaluate dose-limiting toxicities (DLTs). Its secondary endpoints are objective response rate (ORR) and pharmacokinetics. CD166 PDC...
...protein antigen coupled to DM4. CytomX Therapeutics Inc. (NASDAQ:CTMX), South San Francisco, Calif. Product: CD166 PDC (CX-2009...
BioCentury | Nov 12, 2015
Product R&D

Probodies, anticancer

...TNBC), non-small cell lung cancer (NSCLC) or ovarian cancer xenografts, a CD166 probody-drug conjugate ( CD166 PDC...
...toward nomination of a clinical candidate. The company plans to begin clinical testing of an CD166 PDC...
Items per page:
1 - 5 of 5